[2R-(2α,3β,4β)]-3,4-Epoxytetrahydro-2-[[(4-methoxyphenyl)diphenylmethoxy]methyl]furan

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: [2R-(2α,3β,4β)]-3,4-Epoxytetrahydro-2-[[(4-methoxyphenyl)diphenylmethoxy]methyl]furan
• 英文别名: (1R,2R,5R)-2-[[(4-methoxyphenyl)-diphenylmethoxy]methyl]-3,6-dioxabicyclo[3.1.0]hexane
• 化学式: C₂₅H₂₄O₄
• 分子量: 388.463
• InChiKey: UWPIRQGTULSQSD-SMIHKQSGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  40.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [2R-(2α,3β,4β)]-3,4-Epoxytetrahydro-2-[[(4-methoxyphenyl)diphenylmethoxy]methyl]furan 在 4-二甲氨基吡啶 、 lithium aluminium deuteride 、 偶氮二异丁腈 、 三正丁基氢锡 作用下， 以 四氢呋喃 、 甲苯 、 乙腈 为溶剂， 生成 (2S,4R)-2-(((4-methoxyphenyl)diphenylmethoxy)methyl)tetrahydrofuran-4-d
  参考文献：
  名称：

  gauche 和异头效应如何驱动核苷的呋喃戊糖部分的假旋转平衡？

  摘要：

  无碱基 1-脱氧糖 1,2 和 3 以及 2',3'-双脱氧-(ddA (6)、ddG (7)、ddC (S))、2'-脱氧-( dA (9)、dG (lo)、dC (ll)) 和 ribo-@-D-核苷（Ade (12)、Gua (13)、Cyt (14)）是通过邻位质子-质子分析建立的从其 500-MHz 1H-NMR 谱中提取的耦合常数以 20 K 间隔记录，温度范围为 278 至 358 K，D2O 溶液。(S)-四氢糠醇 (l)、2-(S)-(羟甲基)-4-(R)-氘代四氢呋喃 (4) 和 2-(S)-(羟甲基)-3- 的两种新型氘代类似物(S)-氘代四氢呋喃 (5)，已在其 'H-NMR 谱中明确指定了复杂的九自旋系统。(In(&/&)) 作为 1 / Tgave AH' 和 AS' 的函数的范特霍夫图 呋喃戊糖 1-3 中的假旋转平衡值和核苷 614 中的呋喃戊糖部分的值。将

  DOI：

  10.1021/ja00074a046
• 作为产物：
  描述：

  2,3,5-tri-O-acetyl-1,4-anhydro-D-xylitol 在 吡啶 、 sodium hydroxide 、 sodium methylate 作用下， 以 甲醇 为溶剂， 生成 [2R-(2α,3β,4β)]-3,4-Epoxytetrahydro-2-[[(4-methoxyphenyl)diphenylmethoxy]methyl]furan
  参考文献：
  名称：

  gauche 和异头效应如何驱动核苷的呋喃戊糖部分的假旋转平衡？

  摘要：

  无碱基 1-脱氧糖 1,2 和 3 以及 2',3'-双脱氧-(ddA (6)、ddG (7)、ddC (S))、2'-脱氧-( dA (9)、dG (lo)、dC (ll)) 和 ribo-@-D-核苷（Ade (12)、Gua (13)、Cyt (14)）是通过邻位质子-质子分析建立的从其 500-MHz 1H-NMR 谱中提取的耦合常数以 20 K 间隔记录，温度范围为 278 至 358 K，D2O 溶液。(S)-四氢糠醇 (l)、2-(S)-(羟甲基)-4-(R)-氘代四氢呋喃 (4) 和 2-(S)-(羟甲基)-3- 的两种新型氘代类似物(S)-氘代四氢呋喃 (5)，已在其 'H-NMR 谱中明确指定了复杂的九自旋系统。(In(&/&)) 作为 1 / Tgave AH' 和 AS' 的函数的范特霍夫图 呋喃戊糖 1-3 中的假旋转平衡值和核苷 614 中的呋喃戊糖部分的值。将

  DOI：

  10.1021/ja00074a046

文献信息

• Purinyl and pyrimidinyl tetrahydrofurans
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US05272152A1

  公开（公告）日：1993-12-21

  Antiviral activity is exhibited by compounds having the formula ##STR1## and its pharmaceutically acceptable salts.

  抗病毒活性由具有以下化学式的化合物及其药用盐所展示。
• Anti-infective compositions, methods and systems for treating pathogen-induced disordered tissues
  申请人：Johnson Ron B.

  公开号：US20060135464A1

  公开（公告）日：2006-06-22

  Compositions, methods and systems for treating disordered epithelial tissues, such as is caused by pathogens and/or by toxins produced thereby. The invention relates to the use of an anti-infective and/or antimicrobial active agent in a carrier, with vigorous agitation of the disordered epithelial tissue for topical treatment thereof under such conditions sufficient to achieve clinically discernable improvement of the disordered epithelial tissue. The preferred anti-infective and/or antimicrobial active agent comprises a nucleoside, such as acyclovir, valcyclovir, penciclovir, famciclovir, ganciclovir, cidofovir, adefovir, and tenofovir, and derivatives, analogs, or metabolites thereof, or a mixture thereof, or 1-docosanol, optionally in combination with an organohalide. The inventive compositions and methods may employ the use of an applicator adapted for use in promoting the penetration of the treatment composition and/or the vigorous agitation of the disordered tissue.

  用于治疗紊乱上皮组织的组合物、方法和系统，例如由病原体和/或由此产生的毒素引起的紊乱上皮组织。本发明涉及在载体中使用抗感染和/或抗菌活性剂，并对紊乱的上皮组织进行剧烈搅拌，在足以使紊乱的上皮组织得到临床上可识别的改善的条件下进行局部治疗。优选的抗感染和/或抗菌活性剂包括核苷类药物，如阿昔洛韦、valcyclovir、penciclovir、famciclovir、ganciclovir、cidofovir、adefovir 和 tenofovir 及其衍生物、类似物或代谢物，或其混合物，或 1-docosanol，可选择与有机卤化物结合使用。本发明的组合物和方法可以使用适用于促进治疗组合物渗透和/或剧烈搅拌紊乱组织的涂抹器。
• US20140274939A1
  申请人：——

  公开号：US20140274939A1

  公开（公告）日：2014-09-18
• COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES
  申请人：QUADEX PHARMACEUTICALS, LLC

  公开号：US20150342955A1

  公开（公告）日：2015-12-03

  Kits and methods for treating disordered or infected tissue caused by a virus in a mammal involve co-administering a systemic anti-virus drug and topically administered anti-infective composition. The systemic anti-virus drug is internally administered and disrupts or inhibits virus replication systemically within the mammal. Examples include nucleoside analogues, nucleoside analogue precursors, and nucleotide analogues. The topically administered anti-infective composition includes at least one anti-infective agent, such as an organohalide (e.g., benzalkonium chloride), and is formulated to penetrate below the skin surface and allow the anti-infective agent to kill viruses at the infected tissue site. The topical anti-infective composition renders the systemic anti-virus drug more efficacious and reduces the time and/or number of dosages otherwise required for the systemic anti-virus drug to treat the disordered tissue. In some cases, the topical anti-infective composition is more beneficial than the systemic anti-virus drug in killing viruses and can reduce or eliminate post-herpetic neuralgia.
• COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE
  申请人：QUADEX PHARMACEUTICALS, LLC

  公开号：US20150374704A1

  公开（公告）日：2015-12-31

  Compositions and methods for treating disordered and/or prodromal stage tissue infected with by a virus in a mammal by co-administering a systemic anti-virus drug and topically administered anti-infective composition. The systemic anti-virus drug is internally administered and disrupts or inhibits virus replication systemically within the mammal. Examples include nucleoside analogues, nucleoside analogue precursors, and nucleotide analogues. The topically administered anti-infective composition includes at least one anti-infective agent, such as an organohalide (e.g., benzalkonium chloride), and is formulated to penetrate below the skin surface and allow the anti-infective agent to kill viruses at a treatment site. The topical anti-infective composition enhances efficacy of the systemic anti-virus drug and reduces the time and/or number of dosages otherwise required for the systemic anti-virus drug to treat the viral infection. The topical anti-infective composition can be more beneficial than the systemic anti-virus drug in killing viruses and can reduce or eliminate post-herpetic neuralgia.